The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Open accessAbstract
Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the adenosine triphosphate–binding site of the human cyclin-dependent kinase 2 (CDK2). By iterating chemical library synthesis and biological screening, potent inhibitors of the human CDK2–cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified. The structural basis for the binding affinity and selectivity was determined by analysis of a three-dimensional crystal structure of a CDK2-inhibitor complex. The cellular effects of these compounds were characterized in mammalian cells and yeast. In the latter case the effects were characterized on a genome-wide scale by monitoring changes in messenger RNA levels in treated cells with high-density oligonucleotide probe arrays. Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may lead to the development of new therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995) · Science · doi:10.1126/science.270.5235.467 · Cited by 9,609
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Expression monitoring by hybridization to high-density oligonucleotide arrays
Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Norton, H., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt1296-1675 · Cited by 2,840
Self-citationCYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Self-citationGenome-wide expression monitoring in Saccharomyces cerevisiae
Wodicka, L., Dong, H., Mittmann, M., Ho, M.-H., & Lockhart, D. J. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1359 · Cited by 973
Self-citationStrategies for epitope analysis using peptide synthesis
Geysen, H. M., Rodda, S. J., Mason, T. J., Tribbick, G., & Schoofs, P. G. (1987) · Journal of Immunological Methods · doi:10.1016/0022-1759(87)90085-8 · Cited by 868
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Self-citationRuis, H., & Schüller, C. (1995) · BioEssays · doi:10.1002/bies.950171109 · Cited by 416
Protein kinase activity associated with the product of the yeast cell division cycle gene CDC28.
Reed, S. I., Hadwiger, J. A., & Lörincz, A. T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4055 · Cited by 359
C_H…O hydrogen bonding in biology
Wahl, M. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01004-9 · Cited by 323
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Self-citationFunctional Discovery via a Compendium of Expression Profiles
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00015-5 · Cited by 2,533
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
High density synthetic oligonucleotide arrays
Lipshutz, R. J., Fodor, S. P. A., Gingeras, T. R., & Lockhart, D. J. (1999) · Nature Genetics · doi:10.1038/4447 · Cited by 2,205
Self-citationProtein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Genomics, gene expression and DNA arrays
Lockhart, D. J., & Winzeler, E. A. (2000) · Nature · doi:10.1038/35015701 · Cited by 2,053
Self-citationA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Self-citationThe cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
Dissecting the regulatory circuitry of a eukaryotic genome
Holstege, F. C. P., Jennings, E. G., Wyrick, J. J., Lee, T. I., Hengartner, C. J., Green, M. R., Golub, T. R., Lander, E. S., & Young, R. A. (1998) · Cell · doi:10.1016/s0092-8674(00)81641-4 · Cited by 1,670
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“Cdk inhibitors (Gray et al., 1988; Hoessel et al., 1999; Fry et al., 2001; Soni et al., 2001; Nahta et al., 2002) might also prove useful in treating tumors that overexpress cyclin D1-Cdk4 or that have lost INK4a function (Figure 3).”
BackgroundPrivileged scaffolds for library design and drug discovery
Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer
Hughes, T. R., Mao, M., Jones, A. R., Burchard, J., Marton, M. J., Shannon, K. W., Lefkowitz, S. M., Ziman, M., Schelter, J. M., Meyer, M. R., et al. (2001) · Nature Biotechnology · doi:10.1038/86730 · Cited by 1,298
The influence of natural products upon drug discovery (Antiquity to late 1999)
Newman, D. J., Cragg, G. M., & Snader, K. M. (2000) · Natural Product Reports · doi:10.1039/a902202c · Cited by 1,293
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Self-citationA chemical switch for inhibitor-sensitive alleles of any protein kinase
Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., et al. (2000) · Nature · doi:10.1038/35030148 · Cited by 1,031
Self-citationSurvivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Self-citationCyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
Self-citationDNA microarrays in drug discovery and development
Debouck, C., & Goodfellow, P. N. (1999) · Nature Genetics · doi:10.1038/4475 · Cited by 652
Joyce, D. E., Gelbert, L., Ciaccia, A., DeHoff, B., & Grinnell, B. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100017200 · Cited by 648
Drug target validation and identification of secondary drug target effects using DNA microarrays
Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., et al. (1998) · Nature Medicine · doi:10.1038/3282 · Cited by 643
A hierarchical unsupervised growing neural network for clustering gene expression patterns
Herrero, J., Valencia, A., & Dopazo, J. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.2.126 · Cited by 622
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Chao, S.-H., & Price, D. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102306200 · Cited by 621
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
Sulfotransferases: Structure, Mechanism, Biological Activity, Inhibition, and Synthetic Utility
Chapman, E., Best, M. D., Hanson, S. R., & Wong, C. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300631 · Cited by 543
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Self-citationHigh-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Rossi, A. G., Sawatzky, D. A., Walker, A., Ward, C., Sheldrake, T. A., Riley, N. A., Caldicott, A., Martinez-Losa, M., Walker, T. R., Duffin, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1468 · Cited by 509
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Ogawa, N., DeRisi, J., & Brown, P. O. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4309 · Cited by 491
Exploring biology with small organic molecules
Stockwell, B. R. (2004) · Nature · doi:10.1038/nature03196 · Cited by 470
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Meijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454
Self-citationTarget deconvolution strategies in drug discovery
Terstappen, G. C., Schlüpen, C., Raggiaschi, R., & Gaviraghi, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2410 · Cited by 429
Schalley, C. A., Beizai, K., & Vögtle, F. (2001) · Accounts of Chemical Research · doi:10.1021/ar000179i · Cited by 418
Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications
Chung, C. H., & Gillison, M. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0784 · Cited by 418
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25
Leost, M., Schultz, C., Link, A., Wu, Y., Biernat, J., Mandelkow, E., Bibb, J. A., Snyder, G. L., Greengard, P., Zaharevitz, D. W., et al. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01673.x · Cited by 376
Self-citationLam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome Biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 370
Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Self-citationKapahi, P., Takahashi, T., Natoli, G., Adams, S. R., Chen, Y., Tsien, R. Y., & Karin, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007204200 · Cited by 359
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
Self-citationEstablishment of human papillomavirus infection requires cell cycle progression
Pyeon, D., Pearce, S. M., Lank, S. M., Ahlquist, P., & Lambert, P. F. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000318 · Cited by 348
“cells treated with the CDK1 inhibitor, purvalanol A [19].”
BackgroundTargeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
Senderowicz, A. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006353008903 · Cited by 330
The purines: Potent and versatile small molecule inhibitors and modulators of key biological targets
Legraverend, M., & Grierson, D. S. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.060 · Cited by 330
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Self-citationActivation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs
Lochhead, P. A., Sibbet, G., Morrice, N., & Cleghon, V. (2005) · Cell · doi:10.1016/j.cell.2005.03.034 · Cited by 323
A p34cdc2 survival checkpoint in cancer
O'Connor, D. S., Wall, N. R., Porter, A. C. G., & Altieri, D. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00084-3 · Cited by 315
Lüders, J., Patel, U. K., & Stearns, T. (2006) · Nature Cell Biology · doi:10.1038/ncb1349 · Cited by 313
Strength of the CαH··O Hydrogen Bond of Amino Acid Residues
Scheiner, S., Kar, T., & Gu, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010770200 · Cited by 305
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
Walsh, D. P., & Chang, Y.-T. (2006) · Chemical Reviews · doi:10.1021/cr0404141 · Cited by 296
Monitoring gene expression using DNA microarrays
Harrington, C. A., Rosenow, C., & Retief, J. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00091-6 · Cited by 289
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Tao, W., South, V. J., Zhang, Y., Davide, J. P., Farrell, L., Kohl, N. E., Sepp-Lorenzino, L., & Lobell, R. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.003 · Cited by 273
Chang, Y.-T., Gray, N. S., Rosania, G. R., Sutherlin, D. P., Kwon, S., Norman, T. C., Sarohia, R., Leost, M., Meijer, L., & Schultz, P. G. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80048-9 · Cited by 268
Self-citationBenson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252
Self-citationCR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Self-citationRoscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
Self-citationVermeulen, K., Strnad, M., Kryštof, V, Havlícěk, L., Van der Aa, A., Lenjou, M., Nijs, G., Rodrigus, I., Stockman, B., van Onckelen, H., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402378 · Cited by 61
Metadata
- Authors
- Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S.-H., Lockhart, D. J., & Schultz, P. G.
- Venue
- Science
- Published
- 1998-07-24
- Volume
- 281
- Issue
- 5376
- Pages
- 533-538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2097981550
- Cited by
- 808
- References
- 22
- FWCI
- 103.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.